Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Letetresgene autoleucel - US WorldMeds

Next Previous
Drug Profile

Letetresgene autoleucel - US WorldMeds

Alternative Names: GSK 794; GSK-3377794; lete-cel; NY-ESO SPEAR T-cell therapy - GlaxoSmithKline; NY-ESO TCR therapeutic; NY-ESO-1 T cell receptor; NY-ESO-1 TCR T; NY-ESO-1-specific T-cells - Adaptimmune; NY-ESO-1/LAGE-1-modified T-cells; NY-ESO-1c259T; NY-ESO-1c259-antigen-specific-T-cell-receptor-gene-therapy; NY-ESO-1c259-modified-T-cells; NY-ESO-1c259-TCR-transduced-lymphocytes; NY-ESO-1c259-TCR-transduced-T-cells; NY-ESO-c259T

Latest Information Update: 12 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Adaptimmune
  • Developer Adaptimmune; GlaxoSmithKline; GSK; Merck & Co
  • Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Synovial sarcoma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Gastrointestinal cancer; Liposarcoma; Malignant melanoma; Multiple myeloma; Non-small cell lung cancer; Ovarian cancer; Synovial sarcoma
  • No development reported Liver cancer; Prostate cancer

Most Recent Events

  • 04 Aug 2025 US WorldMeds acquires letetresgene autoleucel from Adaptimmune
  • 31 Jul 2025 Adaptimmune Therapeutics intends to initiate a rolling BLA submission in 2025
  • 31 May 2024 Efficacy and adverse event data from the phase II IGNYTE-ESO trial in Synovial sarcoma presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top